StockData
Mirum Pharmaceuticals, Inc. logo

Mirum Pharmaceuticals, Inc. (MIRM) stock

MIRMNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 5/30
$91.95+0.37 (+0.40%)

Close on Nov 17, 2026Market cap $5.97BP/E –Yield –

Mirum Pharmaceuticals operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Mirum Pharmaceuticals's operating cash flow for the twelve months ending Jun 30, 2026 was -$227.27M, down 2626.6% year over year. For fiscal 2025 it was $55.83M, up 440.7% from the year before. The highest annual figure on record is $55.83M in fiscal 2025.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025$55.83M+440.7%
FY2024Dec 31, 2024$10.33M–
FY2023Dec 31, 2023-$70.94M–
FY2022Dec 31, 2022-$120.14M–
FY2021Dec 31, 2021-$132.76M–
FY2020Dec 31, 2020-$89.08M–
FY2019Dec 31, 2019-$39.36M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$44.25M-467.5%
Q1 FY2026Mar 31, 2026-$228.76M–
Q4 FY2025Dec 31, 2025$6.07M–
Q3 FY2025Sep 30, 2025$39.68M+896.0%
Q2 FY2025Jun 30, 2025$12.04M–
Q1 FY2025Mar 31, 2025-$1.96M-112.9%
Q4 FY2024Dec 31, 2024-$5.07M–
Q3 FY2024Sep 30, 2024$3.98M–
Q2 FY2024Jun 30, 2024-$3.80M–
Q1 FY2024Mar 31, 2024$15.21M–
Q4 FY2023Dec 31, 2023-$16.62M–
Q3 FY2023Sep 30, 2023-$18.22M–
Q4 FY2022Dec 31, 2022-$34.27M–
Q3 FY2022Sep 30, 2022-$26.03M–
Q2 FY2022Jun 30, 2022-$20.17M–
Q1 FY2022Mar 31, 2022-$39.67M–
Q4 FY2021Dec 31, 2021-$33.15M–
Q3 FY2021Sep 30, 2021-$34.20M–
Q2 FY2021Jun 30, 2021-$40.20M–
Q1 FY2021Mar 31, 2021-$25.21M–
Q4 FY2020Dec 31, 2020-$36.28M–
Q3 FY2020Sep 30, 2020-$17.45M–
Q2 FY2020Jun 30, 2020-$16.99M–
Q1 FY2020Mar 31, 2020-$18.35M–
Q4 FY2019Dec 31, 2019-$13.70M–
Q3 FY2019Sep 30, 2019-$15.22M–
Q2 FY2019Jun 30, 2019-$8.02M–
Q1 FY2019Mar 31, 2019-$2.43M–

More Mirum Pharmaceuticals figures

See a number that looks wrong?